Literature DB >> 12085937

Stem cell research: a target article collection: Part I--Jordan's banks, a view from the first years of human embryonic stem cell research.

Laurie Zoloth1.   

Abstract

This essay will address the ethical issues that have emerged in the first considerations of the newly emerging stem cell technology. Many of us in the field of bioethics were deliberating related issues as we first learned of the new science and confronted the ethical issues it raised. In this essay, I will draw on the work of colleagues who were asked to reflect on the early stages of the research (members of the IRBs, the Geron Ethicist Advisory Board, and the National Bioethics Advisory Commission) as the field debated the issues of consent, moral status, use of animal tissues, abortion, use of fetal tissue, and the nature and goals of entrepreneurial research. In this new capacity, ethicists weighed the problem of privacy, the role of justice considerations, and the issues of the marketplace in science. At this point, it is clear that far more issues remain unresolved than are settled, that there is largely unexplored territory ahead, and that the single most important task that faces us as a field is a steady call for ongoing conversation and public debate.

Entities:  

Keywords:  Analytical Approach; Biomedical and Behavioral Research; Genetics and Reproduction; Geron Corp.; Geron Ethics Advisory Board; National Bioethics Advisory Commission

Mesh:

Year:  2002        PMID: 12085937     DOI: 10.1162/152651602317267772

Source DB:  PubMed          Journal:  Am J Bioeth        ISSN: 1526-5161            Impact factor:   11.229


  2 in total

1.  The gap between law and ethics in human embryonic stem cell research: overcoming the effect of U.S. federal policy on research advances and public benefit.

Authors:  Patrick L Taylor
Journal:  Sci Eng Ethics       Date:  2005-10       Impact factor: 3.525

2.  Ethical perspectives on knowledge translation in rehabilitation.

Authors:  John D Banja; Arri Eisen
Journal:  Arch Phys Med Rehabil       Date:  2012-11-17       Impact factor: 3.966

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.